OPTIMISATION OF THERAPY FOR GENOTYPE 1 HCV IN RUSSIA CLINICIAN'S VIEW
https://doi.org/10.22328/2077-9828-2014-6-4-88-91
Abstract
In primary HCV patints, Simeprevir as a component of combined antiviral therapy provides for stavle virological responces in 80,4% of cases vs. 50% in control (QUEST-1+QUEST-2).
About the Author
S. N. Kizhlo
Saint-Petersburg Center for Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
References
1. Jacobson I., Dore G.J., Foster G.R. Fried M.W., Radu M., Rafalskiy V.V., Moroz L., Craxi A., Peeters M., Lenz O., Ouwerkerk-Mahadevan S., Kalmeijer R., Beumont-Mauviel M. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naive patients: results from QUEST-1, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013, Amsterdam, Netherlands; abstract 1425.- URL: http://www.natap.org/2013/EASL/EASL_106.htm
2. Jacobson I.M., Dore G.J., Foster G. et al. Simeprevir (TMC435) with Peginterferon/ Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-1, a Phase III Trial. Digestive Disease Week, Orlando, 2013.- A. Sa2072.
3. Manns M., Marcellin P., Poordad F.P., Stanislau Affonso de Araujo E., Buti M., Horsmans Y., Janczewska E., Villamil F., Peeters M., Lenz O., Ouwerkerk-Mahadevan S., Kalmeijer R., Beumont-Mauviel M. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naive patients: results from QUEST-2, a phase III trial. 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013, Amsterdam, Netherlands; abstract 1413.- URL: http://www.natap.org/2013/EASL/EASL_106.htm
4. Poordad F., Manns M.P., Marcellin P. et al. Simeprevir (TMC435) with Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial. Digestive Disease Week, Orlando, 2013, A. 869a.
5. Руководство EACS, 2013 год. / EACS Брюссель, 2013.- URL:http://arvt.ru/news/2013-10-30-EACS7.0.html.- 82 с.
6. Dieterich D., Rockstroh J., Orkin C. Simeprevir (TMC435) Plus PegIFN/Ribavirin in HCV Genotype-1/HIV-1 Coinfection (Study C212). 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014; abstract 24.- URL: http://www.natap.org/2014/CROI/croi_110.htm.
Review
For citations:
Kizhlo S.N. OPTIMISATION OF THERAPY FOR GENOTYPE 1 HCV IN RUSSIA CLINICIAN'S VIEW. HIV Infection and Immunosuppressive Disorders. 2014;6(4):88-91. (In Russ.) https://doi.org/10.22328/2077-9828-2014-6-4-88-91
Views:
444
.png)
Email this article 